AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 15, 2027

Study Completion Date

July 30, 2028

Conditions
Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

AK112

"1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery."

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06537011 - AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter